NIH grant fuels research to find improved treatments for heart failure, aiming to advance care and enhance outcomes for ...

Furthermore, the virus has been found to significantly damage the heart muscle, causing conditions like heart failure even ...

Capricor announced it intends to file a BLA for deramiocel for treatment of patients with DMD cardiomyopathy. Click here to ...

Alnylam Pharmaceuticals Inc. (ALNY) said that new data from the HELIOS-B Phase 3 study of vutrisiran showed that the drug attenuated ...

Edgewise Therapeutics (NASDAQ: EWTX) is up 50% in a single session and 450% from recent lows for a reason. Its novel, oral, ...

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Capricor Therapeutics (CAPR – Research Report). The ...

With the recipient facing extreme breathing difficulty, a heart transplant was the only option left. While his family waited ...

Discover BridgeBio Pharma's groundbreaking patent for treating ATTR cardiomyopathy with Compound 1, showcasing improved patient outcomes and reduced mortality rates.

Shares of biopharma outfit Edgewise Therapeutics ( EWTX -4.14%) soared more than 50% today, reaching a three-year high ...

Arrhythmogenic right ventricular cardiomyopathy (ARVC), also known as arrhythmogenic cardiomyopathy ... If you have ARVC, a ...

Approximately 7%–13% of patients may have left ventricular outflow tract obstruction caused by basal left ventricular hypercontractility.4 Treatment is supportive and guided by hemodynamics and the ...

Rocket Pharmaceuticals announced enrollment completion for phase 2 study using its gene therapy RP-A501 for treatment of male ...